Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Dementia specialists face longer waitlists primarily because demand for their expertise has skyrocketed while the specialist workforce has failed to keep pace. The number of people living with Alzheimer’s disease and other forms of dementia in the United States is projected to nearly triple by 2060, while the number of geriatricians and neurologists specializing in cognitive disorders has remained relatively flat. A patient seeking an evaluation with a dementia specialist today may wait six months to over a year in many regions—a delay that can mean missing the window for early intervention with medications like lecanemab, which shows greater efficacy when administered earlier in disease progression.
The shortage stems from multiple converging factors: long training pathways that discourage entry into the field, geographic clustering of specialists in major metropolitan areas that leaves rural regions severely underserved, reimbursement rates that make dementia care financially less attractive than other specialties, and accelerating burnout among existing specialists. Unlike trendy specialties that attract talent through prestige or earning potential, dementia care offers neither, despite being increasingly essential to the healthcare system. The practical consequence is that many primary care physicians and geriatric generalists who lack subspecialty training are forced to manage complex dementia cases, leading to missed diagnoses, delayed treatment, and lower-quality care across the board. For families already struggling with a loved one’s cognitive decline, the inability to access specialist evaluation compounds the stress and uncertainty of an already difficult situation.
Table of Contents
- THE DEMOGRAPHICS DRIVING UNPRECEDENTED DEMAND
- THE BROKEN TRAINING PIPELINE
- BURNOUT AND WORKFORCE RETENTION CRISIS
- REIMBURSEMENT AND INSURANCE BARRIERS
- GEOGRAPHIC MALDISTRIBUTION AND ACCESS GAPS
- THE IMPACT OF COVID-19 ON SPECIALIST CAPACITY
- THE TREATMENT ACCELERATION PARADOX
THE DEMOGRAPHICS DRIVING UNPRECEDENTED DEMAND
The U.S. population aging at unprecedented rates is the fundamental driver of specialist demand. The Baby Boom generation—roughly 73 million Americans born between 1946 and 1964—is now entering the age range where dementia incidence rises sharply. Alzheimer’s disease affects 1 in 9 Americans age 65 and older, but that figure climbs to approximately 1 in 3 for those over 85. As these cohorts move through their later years, the absolute number of people requiring dementia assessment and ongoing specialist management will grow substantially. The CDC projects that by 2050, the number of Americans age 85 and older will triple, while those 65 and older will more than double.
Dementia prevalence scales directly with advanced age, meaning the demand for specialists will surge far beyond current capacity. Yet medical schools and residency programs have not ramped up training in geriatrics and neurology subspecialties at anywhere near the rate needed to match this demographic shift. A geriatrician graduating today was trained in a system designed for a population that peaked two decades ago. Geographic variation reveals the strain most clearly. Metropolitan areas with academic medical centers can distribute specialist demand across multiple providers, though even these regions report significant waiting times. Rural counties often lack any dementia specialist at all, forcing patients to travel hours for an evaluation or forgo specialist care entirely.
THE BROKEN TRAINING PIPELINE
Becoming a dementia specialist requires a long pathway that discourages talented physicians from entering the field. After four years of medical school, aspiring neurologists complete a three-year neurology residency, then a two to three-year fellowship in behavioral neurology, cognitive neurology, or dementia care. Geriatricians follow a similar lengthy track: four years of medical school, three years of internal medicine residency, then a one to two-year geriatric fellowship. This 9-to-12-year training commitment means a specialist doesn’t begin independent practice until their early to mid-30s. During those years of lower-paid training, physicians accumulate substantial debt—the average medical school graduate carries over $200,000 in educational loans.
Upon completing fellowship, many newly minted dementia specialists discover that reimbursement for cognitive assessments, dementia management, and specialist consultation is lower than for higher-paying specialties like cardiology, orthopedic surgery, or interventional radiology. A neurologist seeing a patient for a complex dementia workup may spend two to three hours on testing, history-taking, and detailed family consultation, only to receive a reimbursement rate that reflects far less time and complexity than other specialist evaluations. This mismatch between training investment and financial return has a predictable effect: many talented physicians choose different specialties, and existing specialists experience burnout. Medical schools report difficulty recruiting medical students into neurology, particularly into dementia-focused tracks. The pipeline is constricted at every stage—too few entering neurology, too few of those choosing dementia subspecialization, and too many of those who do burning out and leaving clinical practice.
BURNOUT AND WORKFORCE RETENTION CRISIS
Dementia care differs fundamentally from many other medical specialties in that there are no curative treatments. Neurologists treating Parkinson’s disease or epilepsy can offer interventions that halt or reverse symptoms. Dementia specialists, until very recently, had only symptomatic medications of marginal benefit and supportive counseling. This therapeutic limitation creates a unique psychological burden: physicians are caring for patients experiencing relentless cognitive decline while having little to offer except delay and management of behavioral symptoms. The work is emotionally taxing because it involves frequent discussions with families about loss, end-of-life care, and the realities of progressive disability.
Specialists must spend considerable time addressing caregiver burden, planning for future incapacity, and managing the grief process—work that is essential but unrewarding from a purely clinical outcomes perspective. Burnout rates among geriatricians and neurologists specializing in dementia are significantly higher than in many other medical fields, with reports suggesting over half of specialists experience moderate to severe burnout. Compounding this are the administrative burdens of modern medicine: prior authorization requirements for testing and medications, electronic health record documentation that consumes hours per day, and insurance denials that frustrate both physician and patient. A specialist who might see 15-20 patients per week may spend 10-15 hours on administrative tasks unrelated to direct care. When burnout occurs, many specialists reduce their patient panels, retire early, or transition to non-clinical roles. This attrition further reduces available capacity without being replaced by new specialists entering the field.
REIMBURSEMENT AND INSURANCE BARRIERS
Medicare and most insurance plans reimburse dementia-related evaluations at rates that haven’t kept pace with the time and complexity involved. A comprehensive initial dementia evaluation—which includes detailed history from both patient and collateral sources, neuropsychological screening, laboratory and imaging review, and counseling about diagnosis, prognosis, and care planning—may take 90 to 120 minutes but be reimbursed at rates equivalent to a 30-minute follow-up visit for a controlled condition. Private insurers often apply additional barriers through prior authorization requirements for specialist consultations, neuropsychological testing, and emerging dementia medications. While medications like lecanemab (Leqembi) and donanemab (Kisunla) offer modest slowing of cognitive decline in early disease, insurance authorization processes can be time-consuming, with rejections requiring appeals that further delay treatment.
Some patients abandon the process entirely due to the bureaucratic friction, while specialists face resource-intensive authorization work that competes for time with patient care. Medicare’s physician fee schedule has not substantially increased for cognitive assessment and management relative to other services, meaning the real (inflation-adjusted) reimbursement for dementia care has effectively declined over the past decade. This creates a financial incentive for physicians to see patients with higher-reimbursement conditions, whether or not they have expertise in those areas. A primary care physician with a limited time slot will be reimbursed similarly for a complex dementia consultation or a straightforward hypertension follow-up, so the incentive structure actually discourages specialist engagement with dementia cases.
GEOGRAPHIC MALDISTRIBUTION AND ACCESS GAPS
Dementia specialists are heavily concentrated in major metropolitan areas and regions with academic medical centers. New York City, Boston, Los Angeles, and San Francisco have multiple specialists and still experience significant wait times. Meanwhile, large swaths of rural America have no dementia specialist within a 100-mile radius. Patients in these regions face an impossible choice: travel long distances for specialist care that may be unavailable anyway, or rely on primary care physicians who lack specific training in dementia diagnostics. This geographic inequality has real consequences for diagnostic accuracy and early intervention.
A patient in a rural region presenting with cognitive complaints may receive a depression diagnosis and be started on an antidepressant without formal cognitive assessment, missing the window for disease-modifying therapy. Specialist knowledge about how dementia presents across different populations—ethnic and cultural factors affecting symptoms, atypical presentations in younger patients, the distinction between mild cognitive impairment and dementia—concentrates in urban centers where diverse patient populations seek specialist care. Rural telemedicine offers partial solutions but faces its own barriers: broadband infrastructure limitations in many agricultural regions, patient comfort with video-based cognitive assessment, and regulatory restrictions on cross-state specialist practice. Some states restrict licensing reciprocity, meaning a dementia specialist in one state cannot legally provide telehealth to patients in a neighboring state despite being equally qualified. These regulatory barriers, while well-intentioned from a consumer protection standpoint, further fragment an already fragmented specialist workforce.
THE IMPACT OF COVID-19 ON SPECIALIST CAPACITY
The COVID-19 pandemic accelerated existing burnout trends among healthcare providers. Neurologists and geriatricians faced disproportionate stress due to the high prevalence of severe COVID-19 in elderly patients and those with neurological conditions. Delirium and acute encephalopathy associated with COVID-19 created surge demand for neurological expertise. Simultaneously, specialists faced social isolation, moral injury from resource rationing, and added occupational risk.
Some chose to retire early or reduce clinical hours, permanently reducing capacity. Telehealth expansion during the pandemic showed promise for improving access to specialists, but integration into routine practice has been uneven. Many dementia specialists struggled to conduct adequate cognitive assessment via video, particularly for patients with moderate to advanced dementia or hearing/vision impairment. Reimbursement for telehealth services was initially limited and remains inconsistent across insurers. The pandemic-era “escape” from high-stress clinical work tempted many specialists to move into administration, research, or part-time hybrid roles, further reducing frontline capacity.
THE TREATMENT ACCELERATION PARADOX
Until 2023, dementia care faced a cruel irony: specialists had limited disease-modifying treatments to offer, which reduced motivation for early diagnosis and specialist referral. Primary care physicians reasoned that if there was nothing to do beyond supportive care, referral to a busy specialist could wait. This changed with FDA approval of lecanemab in January 2023 and subsequent approvals of donanemab and aducanumab. These monoclonal antibodies targeting amyloid beta slow cognitive decline by 25-35% in early symptomatic disease—a modest benefit, but the first treatment showing genuine disease modification.
Paradoxically, this therapeutic advance has worsened waitlist pressures. Patients, families, and primary care physicians now recognize that early specialist evaluation is critical because the medications work best in early disease stages. Yet the same specialist infrastructure that was insufficient before cannot accommodate this surge in referrals. A patient who might have waited months for a specialist appointment under the old paradigm now faces urgent pressure to be evaluated quickly—pressure the system cannot absorb. The treatment advance has revealed the depth of the capacity crisis rather than solving it.
- —
